Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VS-TC
- Development stage
- Unknown
- Lead developer
- Istituto Giannina Gaslini
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
VS-TC is an adoptive T-cell therapy developed by the Istituto Giannina Gaslini for the treatment and prevention of refractory viral infections in immunocompromised patients, particularly those undergoing hematopoietic stem cell transplantation (HSCT). The therapy consists of donor-derived T cells that are ex vivo stimulated and selected to recognize antigens from four common opportunistic viruses: Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Adenovirus (AdV), and BK polyomavirus (BKV). By restoring protective cellular immunity, VS-TC aims to control viral replication and clear infections without inducing significant graft-versus-host disease (GvHD), as the alloreactive T-cell population is typically depleted or the virus-specific population is highly enriched during the manufacturing process. The product is often generated using automated systems like the CliniMACS Prodigy to ensure standardized production of the multi-specific T-cell population.
- Other names
- virus-specific T cellsmulti-virus-specific T cellsVSTs
02
Targets
EBV-pHLA (Epstein–Barr virus peptide–HLA complex)BK polyomavirus peptide-Human Leukocyte Antigen complexHAdV (Human adenovirus)
Beyond the preview
Go deeper on VS-TC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VS-TC.